Update: Pacira Biosciences Shareholder Seeks Board Changes, Pushes for Sale

MT Newswires Live

01/01

(Updates with Pacira's reply in the third paragraph.)

Pacira Biosciences (PCRX) shareholder, DOMA Perpetual Capital Management, said Tuesday that it plans to nominate three independent director candidates at the company's annual meeting in 2026.

DOMA said it owns about 6.83% of the company's shares and added that it is also calling for an immediate sale of the company, arguing that executive pay and overall spending are "exorbitant and unmerited" and that the board has not provided proper fiduciary oversight.

"Our Board is committed to enhancing long-term shareholder value and we take seriously feedback from our shareholders," Pacira Biosciences told MT Newswires, adding that it remains focused on carrying out its 5x30 strategy to drive growth.

Price: 26.15, Change: +0.08, Percent Change: +0.31

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2600703628"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2600703628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2600703628?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-01 01:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600703628","market":"us","top_or_hot":-1,"title":"Update: Pacira Biosciences Shareholder Seeks Board Changes, Pushes for Sale","media":"MT Newswires Live","content":"<html><body><p> (Updates with Pacira's reply in the third paragraph.)</p><p>Pacira Biosciences (PCRX) shareholder, DOMA Perpetual Capital Management, said Tuesday that it plans to nominate three independent director candidates at the company's annual meeting in 2026.</p><p>DOMA said it owns about 6.83% of the company's shares and added that it is also calling for an immediate sale of the company, arguing that executive pay and overall spending are \"exorbitant and unmerited\" and that the board has not provided proper fiduciary oversight.</p><p>\"Our Board is committed to enhancing long-term shareholder value and we take seriously feedback from our shareholders,\" Pacira Biosciences told MT Newswires, adding that it remains focused on carrying out its 5x30 strategy to drive growth.</p><p>Price: 26.15, Change: +0.08, Percent Change: +0.31</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Update: Pacira Biosciences Shareholder Seeks Board Changes, Pushes for Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpdate: Pacira Biosciences Shareholder Seeks Board Changes, Pushes for Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-01 01:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> (Updates with Pacira's reply in the third paragraph.)</p><p>Pacira Biosciences (PCRX) shareholder, DOMA Perpetual Capital Management, said Tuesday that it plans to nominate three independent director candidates at the company's annual meeting in 2026.</p><p>DOMA said it owns about 6.83% of the company's shares and added that it is also calling for an immediate sale of the company, arguing that executive pay and overall spending are \"exorbitant and unmerited\" and that the board has not provided proper fiduciary oversight.</p><p>\"Our Board is committed to enhancing long-term shareholder value and we take seriously feedback from our shareholders,\" Pacira Biosciences told MT Newswires, adding that it remains focused on carrying out its 5x30 strategy to drive growth.</p><p>Price: 26.15, Change: +0.08, Percent Change: +0.31</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2600703628","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600703628","pubTimestamp":1767200441,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pacira Biosciences  shareholder, DOMA Perpetual Capital Management, said Tuesday that it plans to nominate three independent director candidates at the company's annual meeting in 2026.DOMA said it owns about 6.83% of the company's shares and added that it is also calling for an immediate sale of the company, arguing that executive pay and overall spending are \"exorbitant and unmerited\" and that the board has not provided proper fiduciary oversight.\"Our Board is committed to enhancing long-term shareholder value and we take seriously feedback from our shareholders,\" Pacira Biosciences told MT Newswires, adding that it remains focused on carrying out its 5x30 strategy to drive growth.Price: 26.15, Change: +0.08, Percent Change: +0.31","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PCRX":"Pacira Pharmaceuticals"},"translate_title":"更新：Pacira Biosciences股东寻求董事会变动，推动出售","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCRX":1},"content_text":"(Updates with Pacira's reply in the third paragraph.)Pacira Biosciences (PCRX) shareholder, DOMA Perpetual Capital Management, said Tuesday that it plans to nominate three independent director candidates at the company's annual meeting in 2026.DOMA said it owns about 6.83% of the company's shares and added that it is also calling for an immediate sale of the company, arguing that executive pay and overall spending are \"exorbitant and unmerited\" and that the board has not provided proper fiduciary oversight.\"Our Board is committed to enhancing long-term shareholder value and we take seriously feedback from our shareholders,\" Pacira Biosciences told MT Newswires, adding that it remains focused on carrying out its 5x30 strategy to drive growth.Price: 26.15, Change: +0.08, Percent Change: +0.31","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}